- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04431960
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk
Blackcurrant Modifies Gut Microbiota and Reduces the Risk of Postmenopausal Osteoporosis and Cardiovascular Disease: A Pilot Randomized Clinical Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Postmenopausal bone loss is a primary contributor to osteoporosis and osteoporotic fractures in adult women in menopause transition. By following women over this period, studies have documented distinct patterns of a decrease in estrogen, a natural antioxidant, simultaneously with adverse alterations in body fat distribution, lipids and lipoproteins, and measures of vascular health, which can increase a woman's risk of developing CVD. Overall goal of this project is to evaluate the effects of blackcurrant (BC) supplementation on changes in gut microbiome, bone mass, and CVD risk factors in adult women. For this purpose, the investigators will conduct a pilot randomized placebo-controlled clinical trial with BC supplementation for 6 months in peri- and early postmenopausal women aged 45-60 years.
The primary endpoint will be whole-body bone mineral density (BMD); secondary endpoints will be gut microbiota composition. To delineate the underlying mechanisms of the action, changes in biomarkers for bone metabolism, bone-related immune and endocrine systemic biomarkers, and CVD risk factors by BC supplementation will be measured in plasma and peripheral blood derived mononuclear cells.
The specific objectives of the study are to investigate the effects of BC extract on: 1) bone mass and bone remodeling markers; 2) changes in the gut microbiota abundance and composition, immune and endocrine biomarkers, and CVD risk factors and their relationships with changes in bone mass.
The proposed study will provide novel insight into whether and how BC consumption reduces the risk of postmenopausal bone loss and CVD in adult women and will improve understanding of the clinical roles of gut microbiome in postmenopausal bone loss. Findings from this study will help increase awareness of the bone and heart health promoting effect of BC and motivate increased production of BC and other berry products in response to the increasing consumer demand.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
Storrs, Connecticut, United States, 06269
- University of Connecticut Department of Nutritional Sciences and Kinesiology Human Performance Laboratory
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- perimenopausal or early postmenopausal women aged 45-60 years old
- not on HRT for at least one year before the initiation of the study
- maintaining normal exercise level (<7 h/wk) and willing to avoid exercise 24-h prior to blood and stool sampling and 12-h prior to bone measurements
- willing to ingest a dietary BC supplement or placebo (up to 900 mg/day, two 450 mg capsules) as well as 400 mg calcium and 500 IU vitamin D daily
- willing to avoid other dietary supplements for the duration of the study
- willing to avoid intake of foods extremely rich in anthocyanins and fermented dairy products containing viable Bifidobacteria or Lactobacilli
- willing to have 3 blood draws, 2 stool collections, and 2 bone scans
- willing to take urine pregnancy test if they are perimenopausal.
Exclusion Criteria:
- those with metabolic bone disease, renal disease, cancer, cardiovascular disease, diabetes mellitus, respiratory disease, gastrointestinal disease, liver disease or other chronic diseases
- those with hypertension or on drugs that lower blood pressure
- those with planned surgery during the study period or within 2 weeks of ending the intervention
- taking medications that alter bleeding (such as antiplatelets or anticoagulants) or those with a bleeding disorder
- taking a phenothiazine drug (most commonly used for nausea or mental health conditions)
- having a sensitivity or allergy to any of ingredients for the placebo (rice powder) and calcium/D supplement (calcium citrate, polyethylene glycol, croscarmellose sodium, hydroxypropyl methylcellulose, magnesium stearate, oligofructose enriched inulin, propylene glycol dicaprylate/dicaprate, talc, titanium dioxide, vitamin D3)
- heavy smokers (>20 cigarettes/day)
- perimenopausal women with any chance or plan of pregnancy
- taking prescription medications known to alter bone and Ca metabolism such as calcitonin, bisphosphonates, raloxifene within 3 months before the start of the study
- taking anabolic agents such as parathyroid hormone, growth hormone, or steroids within 3 months before the start of the study
- planning any procedure that includes iodine, barium or nuclear medicine isotopes in next 7 months
- alcohol consumption exceeding 2 drinks/day (approximately 14 g ethanol per drink) or a total of 12/week
- UConn students and/or employees who any key personnel teach or who report to any key personnel
- study key personnel, spouses of key personnel, or dependents/relatives of any key personnel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: low-BC Group
consume: 1) one tablet containing 392 mg blackcurrant (BC) extract per capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
|
A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Other Names:
|
Active Comparator: high-BC Group
consume: 1) two capsules containing 392 mg BC extract per tablet (total 784 mg/day) and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
|
A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Other Names:
|
Placebo Comparator: Control Group
consume: 1) one placebo capsule and 2) one calcium citrate caplet containing 400 mg calcium and 500 IU vitamin D
|
A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bone mineral density (BMD)
Time Frame: from baseline to 6 months
|
changes in BMD of whole-body, head, arms, legs, trunk, ribs, spine, pelvis
|
from baseline to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut microbiota profile
Time Frame: from baseline to 6 months
|
changes in the gut microbial composition
|
from baseline to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum bone metabolism biomarkers
Time Frame: from baseline to 6 months
|
changes in serum concentrations of bone metabolism (BALP, P1NP, CTX-1, OC)
|
from baseline to 6 months
|
Serum inflammation biomarker
Time Frame: from baseline to 6 months
|
changes in serum inflammation biomarker (hs-CRP)
|
from baseline to 6 months
|
Plasma CVD risk factors (lipids, oxidative stress, endothelial function)
Time Frame: from baseline to 6 months
|
changes in plasma CVD risk factors
|
from baseline to 6 months
|
Blood pressure (SBP/DBP), BMI, WC, body composition
Time Frame: from baseline to 6 months
|
changes in blood pressure (SBP/DBP), BMI, WC, body composition
|
from baseline to 6 months
|
Concentrations of plasma IL-1β, IL-6, TNFα, Th17 and Treg
Time Frame: from baseline to 6 months
|
changes in plasma concentrations of immune biomarkers
|
from baseline to 6 months
|
Concentrations of plasma IGF-1 and cGP
Time Frame: from baseline to 6 months
|
changes in plasma concentrations of endocrine biomarkers
|
from baseline to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ock K Chun, PhD, University of Connecticut
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HR20-0035
- 2020-67018-30852 (Other Grant/Funding Number: USDA NIFA)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Our plan of sharing of data generated by this project includes the following:
- Presentations at national scientific meetings. From the projects, it is expected that approximately two presentations at national meetings would be appropriate.
- Publication in peer-reviewed journals. It is our explicit intention that the study findings and key data will be placed in a readily accessible public database. All efforts will be made to rapidly release data through publication of results as quickly as possible following our analysis of the experiment data. Data used in publications will be released in a timely manner.
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on blackcurrant (BC) extract
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
University of ChichesterCompletedno ConditionsUnited Kingdom
-
Johnson & Johnson Vision Care, Inc.CompletedMyopiaUnited States
-
Cifarma Cientifica Farmaceutica LtdaUnknown
-
Coopervision, Inc.Completed
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); University of Victoria; Provincial... and other collaboratorsCompletedObesity | Physical Activity | Physical FitnessCanada
-
Northwestern UniversityThe Chrysalis InitiativeNot yet recruitingQuality of Life | Breast Cancer | ChemotherapyUnited States
-
Pierre Fabre MedicamentCompletedChronic Venous Insufficiency (CVI)France
-
Johnson & Johnson Vision Care, Inc.Coles-Brennan Pty LtdCompleted
-
Bright Cell, Inc.Not yet recruitingNasolabial Fold Wrinkles